Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSALT peptide

            Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 26, 2021

            Details:

            Peter Lougheed Center has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hesperidin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Hesperco

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ingenew Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 17, 2021

            Details:

            Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSALT peptide

            Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2021

            Details:

            The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger ARDS and AKI in patients infected with SARS-CoV-2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSALT peptide

            Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $0.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement December 29, 2020

            Details:

            The proceeds supplement the Government of Canada’s commitment of up to $6.7 million for the Phase II development of Metablok (LSALT Peptide), the Company’s therapeutic drug candidate to prevent organ inflammation and injury in patients hospitalized with COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): QBKPN

            Therapeutic Area: Infections and Infectious Diseases Product Name: QBKPN

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: NRC IRAP

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding December 18, 2020

            Details:

            This help will expedite the clinical development & deployment of QBKPN for significant unmet need for broad innate immune protection of the lungs, particularly in vulnerable populations such as the elderly & those with co-morbid conditions who lack innate immune resiliency.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Palmitoylethanolamide

            Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 15, 2020

            Details:

            FDA has authorized randomized, controlled, double-blind study on 352 patients. The Company is expected to conduct this trial in 25-30 Medical Centers and Hospitals in North America.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Alfa-2B

            Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            In preparation of the Company's preparing human clinical trials of AP-003, the company will obtain trial consent virtually and the trial will be conducted via telemedicine from the participant’s home.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LSALT peptide

            Therapeutic Area: Infections and Infectious Diseases Product Name: Metablok

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            Details:

            The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of organ inflammation known to trigger acute respiratory distress syndrome (and acute kidney injury in COVID-19 patients.